
Opinion|Videos|April 2, 2025
Summarizing Topical Options: Treating Atopic Dermatitis (AD) Across Every Age
Author(s)Lisa Swanson, MD
A panelist discusses how topical treatments for atopic dermatitis can be strategically selected and applied across the lifespan, with considerations for age-specific needs from infancy through adulthood.
Advertisement
Summarizing Topical Options: Treating Atopic Dermatitis (AD) Across Every Age
First-Line Therapies
Emollients and Moisturizers
- Foundation of all AD management regardless of age
- Apply 2-3 times daily, especially after bathing
- Ceramide-containing formulations may provide superior barrier repair
- Ointments preferred for severe dryness; creams and lotions for better cosmetic acceptability
Topical Corticosteroids (TCS)
- Potency selection based on age, location, and severity
- Infants: Low potency only (hydrocortisone 1-2.5%)
- Children: Low to mid-potency for body; low potency for face/intertriginous areas
- Adolescents/Adults: Full potency range appropriate with location-based selection
- Apply once or twice daily during flares
- Proactive twice-weekly application reduces relapse rates
Second-Line Therapies
Topical Calcineurin Inhibitors (TCIs)
- Tacrolimus 0.03% (ages ≥2) and 0.1% (ages ≥16)
- Pimecrolimus 1% (ages ≥2)
- Preferred for face, neck, and intertriginous areas across all age groups
- No risk of skin atrophy; suitable for long-term maintenance
- Initial application burning more pronounced in younger patients
Phosphodiesterase-4 (PDE4) Inhibitors
- Crisaborole 2% ointment approved for ages ≥3 months
- Apply twice daily to affected areas
- Well-tolerated in pediatric populations
- Useful for steroid-sensitive locations
- Consider for maintenance therapy after flare control with TCS
Emerging Options
Topical JAK Inhibitors
- Ruxolitinib 1.5% cream approved for ages ≥12 years
- Not approved for immunocompromised patients
- Rapid itch relief (within 8-12 hours)
- Limited to ≤20% BSA application
- Not recommended for children <12 years pending additional safety data
Antimicrobial Approaches
- Reserved for clinically infected lesions
- Bleach baths (0.005-0.0125%) twice weekly beneficial across all ages
- Antiseptic washes may help manage bacterial colonization
- Antibiotic-containing combination products only for short-term use
Age-Specific Considerations
Infants (0-2 years)
- Emphasize non-pharmacologic approaches
- Limited use of TCS (low potency only)
- Careful attention to application amounts
- Wet wrap therapy effective for severe flares
- Avoid TCIs under age 2 (off-label if used)
Children (2-12 years)
- Education on self-care increasingly important
- Monitor for growth effects with potent TCS
- TCIs and PDE4 inhibitors particularly valuable
- School considerations (treatment timing, stigma)
- Simplified regimens to improve adherence
Adolescents (12-18 years)
- Vehicle selection critical for adherence
- Cosmetically acceptable options for visible areas
- Transition to self-management with supervision
- Consider impact on social development
- Attention to treatment burden during school/activities
Adults (>18 years)
- Occupational considerations for hand dermatitis
- Treatment of specific distribution patterns (head/neck, hand/foot)
- Pregnancy considerations for reproductive-age women
- Focus on long-term maintenance strategies
- Cosmetic aspects may drive vehicle preferences
Practical Treatment Strategies
- "Weekend therapy" maintenance regimen for all ages
- Step-up/step-down approaches based on disease activity
- Rotation between different agent classes for recalcitrant areas
- Written action plans for flare management
- Regular reassessment of treatment effectiveness and side effects
Advertisement
Related to this article

Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.

September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.

EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.

EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.

The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.

The FDA has approved baricitinib for adolescents aged 12 and older with severe alopecia areata, marking the first systemic oral therapy cleared for this population.

Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
Advertisement
Advertisement
Trending on Patient Care Online
1
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
2
5 FDA Decisions for Primary Care to Know from September 2026
3
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5
